Amatuximab and novel agents targeting mesothelin for solid tumors

Paolo Baldo, Sara Cecco

Research output: Contribution to journalReview articlepeer-review


Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in cell adhesion and metastasis. MSLN is prevalent in mesothelia tissues but is expressed in several human cancers, such as OC, pancreatic cancer, mesothelioma, and lung cancer. Amatuximab (MORAb-009) is a mouse-human chimeric monoclonal antibody with a selective affinity for MSLN. The principal mechanism of action comprises inhibition of binding of MSLN with the antigen CA125/MUC16. The highest phase of development is actually a Phase II trial (MORAb-009-201, Europe). In this review, we describe the mechanism of action of amatuximab and other MSLN-targeting novel drugs, along with a discussion about the expected efficacy, safety, and toxicity of this promising group of agents and implications for future research and clinical practice.

Original languageEnglish
Pages (from-to)5337-5353
Number of pages17
JournalOncoTargets and Therapy
Publication statusPublished - Nov 8 2017


  • Amatuximab
  • Antigen
  • Mesothelin
  • Mesothelioma
  • Monoclonal antibody
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Amatuximab and novel agents targeting mesothelin for solid tumors'. Together they form a unique fingerprint.

Cite this